Literature DB >> 32442221

Expression of hepatic stellate cell activation-related genes in HBV-, HCV-, and nonalcoholic fatty liver disease-associated fibrosis.

Lu He1, Hui Yuan1, Junjie Liang2, Jian Hong1,3, Chen Qu3.   

Abstract

Liver fibrosis is a manifestation of chronic liver injury. It leads to hepatic dysfunction and is a critical element in the pathogenesis of cirrhosis and hepatocellular carcinoma. The activation of hepatic stellate cells (HSC) plays a central role in liver fibrogenesis of different etiologies. To elucidate the molecular mechanism of this phenomenon, it is important to analyze the changes in gene expression that accompany the HSC activation process. In this study, we isolated quiescent and activated HSCs from control mice and mice with CCl4-induced liver fibrosis, respectively, and performed RNA sequencing to compare the differences in gene expression patterns between the two types of HSCs. We also reanalyzed public gene expression data for fibrotic liver tissues isolated from patients with HBV infection, HCV infection, and nonalcoholic fatty liver disease to investigate the gene expression changes during liver fibrosis of these three etiologies. We detected 146 upregulated and 18 downregulated genes in activated HSCs, which were implicated in liver fibrosis as well. Among the overlapping genes, seven transcription factor-encoding genes, ARID5B, GATA6, MITF, PBX1, PLAGL1, SOX4, and SOX9, were upregulated, while one, RXRA, was downregulated. These genes were suggested to play a critical role in HSC activation, and subsequently, in the promotion of liver fibrosis. We undertook the RNA sequencing of quiescent and activated HSCs and analyzed the expression profiles of genes associated with HSC activation in liver fibrotic tissues from different liver diseases, and also aimed to elucidate the changes in gene expression patterns associated with HSC activation and liver fibrosis.

Entities:  

Year:  2020        PMID: 32442221     DOI: 10.1371/journal.pone.0233702

Source DB:  PubMed          Journal:  PLoS One        ISSN: 1932-6203            Impact factor:   3.240


  5 in total

1.  microRNA-186 in extracellular vesicles from bone marrow mesenchymal stem cells alleviates idiopathic pulmonary fibrosis via interaction with SOX4 and DKK1.

Authors:  Jing Zhou; Yang Lin; Xiuhua Kang; Zhicheng Liu; Wei Zhang; Fei Xu
Journal:  Stem Cell Res Ther       Date:  2021-02-03       Impact factor: 6.832

2.  miR-654-5p Contributes to the Activation and Proliferation of Hepatic Stellate Cells by Targeting RXRα.

Authors:  Heming Ma; Xiaomei Wang; Xu Liu; Chang Wang; Xiuzhu Gao; Junqi Niu
Journal:  Front Cell Dev Biol       Date:  2022-04-06

Review 3.  Perivascular Mesenchymal Stem/Stromal Cells, an Immune Privileged Niche for Viruses?

Authors:  Grégorie Lebeau; Franck Ah-Pine; Matthieu Daniel; Yosra Bedoui; Damien Vagner; Etienne Frumence; Philippe Gasque
Journal:  Int J Mol Sci       Date:  2022-07-21       Impact factor: 6.208

4.  Hsa-miR-422a Originated from Short Interspersed Nuclear Element Increases ARID5B Expression by Collaborating with NF-E2.

Authors:  Woo Ryung Kim; Eun Gyung Park; Hee-Eun Lee; Sang-Je Park; Jae-Won Huh; Jeong Nam Kim; Heui-Soo Kim
Journal:  Mol Cells       Date:  2022-04-20       Impact factor: 4.250

5.  A type IV Autotaxin inhibitor ameliorates acute liver injury and nonalcoholic steatohepatitis.

Authors:  Anastassis Perrakis; Ruchi Bansal; Richell Booijink; Fernando Salgado-Polo; Craig Jamieson
Journal:  EMBO Mol Med       Date:  2022-07-14       Impact factor: 14.260

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.